OUR RESEARCH
MASH
Targets & Clinical Progress
Posters/Publications
OUR PIPELINE
Pipeline
Clinical Trials
Expanded Access Policy
OUR STORY
Overview
Management Team
Partnership
NEWS
CAREERS
OUR RESEARCH
MASH
Targets & Clinical Progress
Posters/Publications
OUR PIPELINE
Pipeline
Clinical Trials
Expanded Access Policy
OUR STORY
Overview
Management Team
Partnership
NEWS
CAREERS
News
2024
2023
2022
2021
2020
2019
Ascletis Received IND Approval for its NASH Drug
28/08/2019
3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH
01/03/2019
Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing
13/02/2019
